THE Company
JeniVision is an innovative early clinical stage biopharmaceutical company that strives to discover & develop advanced therapies for ocular diseases from the anterior to posterior segments of the eye. Our proprietary non-invasive ocular delivery platform (NIODP) successfully delivered drugs to the retina at high doses. With our creativity and ingenuity, we hope to forge new pathways in medicine for the future.
Pipeline
*GRAS: generally recognized as safe
Jenny WanG
Jenny Wang, PhD, CEO/CSO, is an entrepreneur, an inventor, and a scientist. She also serves as Executive Chairwomen of the JeniVision Board of Directors. She leads and executes business plans for obtaining financing, establishing partnerships, IND filings and intellectual property protection efforts of JeniVision; as well as spearheads pre-clinical research & development, including research, design, and formulation development for JeniVision pipeline. It was through these various activities, she led the discovery of the proprietary non-invasive ocular delivery platform (NIODP), particularly for retinal drug delivery (JV-MD1 and JV-MD2). Under the leadership of Dr. Wang, the company expanded the pipeline for treatment of major ophthalmic diseases to include not only the anterior but also the posterior segments of the eye. Dr. Wang is well-trained in pharmacology, biochemistry, and molecular & cellular biology. She brings over 30-years of experience in academia and pharmaceutical/biotechnology industry, including positions at City of Hope, California Institute of Technology, and Allergan. Her success as a researcher and inventor is evident in over 45 peer reviewed scientific publications and over 45 patents on cancer, ion channel, inflammation, ophthalmology, and hair growth. https://www.linkedin.com/in/dr-jennywwang
Nonna Snider
Nonna Snider, VP Clinical & Operations, joined JeniVision in 2020. She leads clinical research, manages FDA filings, and helps with day-to-day company operations. She has over 20 years of experience in pre-clinical and clinical drug development in both Pharmaceutical Industry and Academia. Mrs. Snider started her research career at Allergan in the Nuclear Receptor group focused on drug discovery in the areas of dermatology, oncology and metabolic disease. She then transitioned to project management in a biotech start-up environment, gaining experience in conducting pre-clinical and clinical research in US, India and Latin America, taking a dermatology and oncology compounds through pre-clinical, Phase I and II clinical trials. Mrs. Snider then joined USC Norris Comprehensive Cancer Center team coordinating Quality Assurance and Data and Safety Monitoring Committees, working within a multidisciplinary team to further grow the QA and DSM programs, and later as the Assistant Director for Clinical Operations at CISO, and was responsible for ensuring safe and compliant implementation of Phase I, II and III oncology clinical trials conducted at USC. https://www.linkedin.com/in/nonna-snider-sheynkman-01b0084